Fulcrum Therapeutics (NASDAQ:FULC) Posts Earnings Results, Misses Expectations By $0.03 EPS

Fulcrum Therapeutics (NASDAQ:FULC) issued its quarterly earnings results on Tuesday. The company reported ($0.31) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.03), Zacks reports.

Fulcrum Therapeutics Stock Down 3.9 %

NASDAQ FULC opened at $3.70 on Tuesday. The company has a market cap of $199.57 million, a price-to-earnings ratio of -11.94 and a beta of 2.03. Fulcrum Therapeutics has a twelve month low of $2.86 and a twelve month high of $13.70. The business’s fifty day moving average is $4.17 and its 200 day moving average is $4.66.

Wall Street Analyst Weigh In

Several research analysts have commented on the stock. Royal Bank of Canada restated a “sector perform” rating and set a $4.00 price objective on shares of Fulcrum Therapeutics in a research report on Thursday, November 14th. HC Wainwright reissued a “neutral” rating and set a $4.00 price target on shares of Fulcrum Therapeutics in a report on Thursday, November 14th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat.com, Fulcrum Therapeutics currently has an average rating of “Hold” and a consensus target price of $9.33.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.